Literature DB >> 26998148

18F-fluoroethyl-L-tyrosine positron emission tomography for the differential diagnosis of tumefactive multiple sclerosis versus glioma: A case report.

Sied Kebir1, Florian C Gaertner2, Marcus Mueller3, Michael Nelles4, Matthias Simon5, Niklas Schäfer1, Moritz Stuplich3, Christina Schaub3, Michael Niessen3, Frederic Mack3, Ralph Bundschuh2, Susanne Greschus4, Markus Essler2, Martin Glas6, Ulrich Herrlinger3.   

Abstract

Large demyelinating inflammatory central nervous system (CNS) lesions may present with contrast enhancement on magnetic resonance imaging and may mimic CNS tumors such as glioma. In ambiguous cases, new diagnostic tools that may be helpful for distinguishing between demyelinating inflammatory and neoplastic CNS lesions are required. The current study presents the case of a patient with a large contrast-enhanced frontal brain lesion, who was initially diagnosed with tumefactive multiple sclerosis. Following the progression of the brain lesion, an 18F-fluoroethyl-L-tyrosine positron emission tomography (18F-FET PET) was performed, revealing markedly elevated static 18F-FET uptake parameters along with time activity-curves consistent with glioma. Subsequently, a biopsy was undertaken, which confirmed the presence of anaplastic oligoastrocytoma. This case illustrates that 18F-FET PET may provide useful diagnostic information in cases where distinction between neoplastic and demyelinating inflammatory CNS lesions is challenging. However, further systematic and prospective analyses are warranted to explore the value of this method in this setting.

Entities:  

Keywords:  18F-fluoroethyl-L-tyrosine positron emission tomography; dynamic 18F-FET PET; glioma; static 18F-FET PET; tumefactive multiple sclerosis

Year:  2016        PMID: 26998148      PMCID: PMC4774557          DOI: 10.3892/ol.2016.4189

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  17 in total

Review 1.  O-(2-[18F]fluoroethyl)-L-tyrosine: uptake mechanisms and clinical applications.

Authors:  Karl-Josef Langen; Kurt Hamacher; Matthias Weckesser; Frank Floeth; Gabriele Stoffels; Dagmar Bauer; Heinz H Coenen; Dirk Pauleit
Journal:  Nucl Med Biol       Date:  2006-04       Impact factor: 2.408

2.  Prognostic value of early [18F]fluoroethyltyrosine positron emission tomography after radiochemotherapy in glioblastoma multiforme.

Authors:  Marc D Piroth; Michael Pinkawa; Richard Holy; Jens Klotz; Sandra Nussen; Gabriele Stoffels; Heinz H Coenen; Hans J Kaiser; Karl J Langen; Michael J Eble
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-06-18       Impact factor: 7.038

3.  Concurrence of glioma and multiple sclerosis.

Authors:  ShahNaz Hayat Khan; Joseph E Buwembo; Q Li
Journal:  Can J Neurol Sci       Date:  2005-08       Impact factor: 2.104

Review 4.  New PET radiopharmaceuticals beyond FDG for brain tumor imaging.

Authors:  B Gulyás; C Halldin
Journal:  Q J Nucl Med Mol Imaging       Date:  2012-04       Impact factor: 2.346

5.  FET PET for the evaluation of untreated gliomas: correlation of FET uptake and uptake kinetics with tumour grading.

Authors:  Gabriele Pöpperl; Friedrich W Kreth; Jan H Mehrkens; Jochen Herms; Klaus Seelos; Walter Koch; Franz J Gildehaus; Hans A Kretzschmar; Jörg C Tonn; Klaus Tatsch
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-09-01       Impact factor: 9.236

6.  [18F]-fluoro-ethyl-L-tyrosine PET: a valuable diagnostic tool in neuro-oncology, but not all that glitters is glioma.

Authors:  Markus Hutterer; Martha Nowosielski; Daniel Putzer; Nathalie L Jansen; Marcel Seiz; Michael Schocke; Mark McCoy; Georg Göbel; Christian la Fougère; Irene J Virgolini; Eugen Trinka; Andreas H Jacobs; Günther Stockhammer
Journal:  Neuro Oncol       Date:  2013-01-17       Impact factor: 12.300

Review 7.  Tumefactive demyelination: an approach to diagnosis and management.

Authors:  Todd A Hardy; Jeremy Chataway
Journal:  J Neurol Neurosurg Psychiatry       Date:  2013-01-19       Impact factor: 10.154

8.  Prognostic value of 18F-fluoroethyl-L-tyrosine PET and MRI in small nonspecific incidental brain lesions.

Authors:  Frank Willi Floeth; Michael Sabel; Gabriele Stoffels; Dirk Pauleit; Kurt Hamacher; Hans-Jakob Steiger; Karl-Josef Langen
Journal:  J Nucl Med       Date:  2008-04-15       Impact factor: 10.057

Review 9.  MRI features of benign multiple sclerosis: toward a new definition of this disease phenotype.

Authors:  M Rovaris; F Barkhof; M Calabrese; N De Stefano; F Fazekas; D H Miller; X Montalban; C Polman; M A Rocca; A J Thompson; T A Yousry; M Filippi
Journal:  Neurology       Date:  2009-05-12       Impact factor: 9.910

10.  Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis.

Authors:  C F Lucchinetti; R H Gavrilova; I Metz; J E Parisi; B W Scheithauer; S Weigand; K Thomsen; J Mandrekar; A Altintas; B J Erickson; F König; C Giannini; H Lassmann; L Linbo; S J Pittock; W Brück
Journal:  Brain       Date:  2008-06-05       Impact factor: 13.501

View more
  9 in total

1.  18F-fluoroethyl-L-tyrosine positron emission tomography-guided diagnosis of a malignant intramedullary spinal cord tumor.

Authors:  Sied Kebir; Okka Kimmich; Pitt Niehusmann; Florian C Gaertner; Markus Essler; Jennifer Landsberg; Thomas Klockgether; Matthias Simon; Ulrich Herrlinger; Martin Glas
Journal:  Oncol Lett       Date:  2016-10-10       Impact factor: 2.967

Review 2.  Pattern Recognition of the Multiple Sclerosis Syndrome.

Authors:  Rana K Zabad; Renee Stewart; Kathleen M Healey
Journal:  Brain Sci       Date:  2017-10-24

3.  Machine learning-based differentiation between multiple sclerosis and glioma WHO II°-IV° using O-(2-[18F] fluoroethyl)-L-tyrosine positron emission tomography.

Authors:  Sied Kebir; Laurèl Rauschenbach; Martin Glas; Manuel Weber; Lazaros Lazaridis; Teresa Schmidt; Kathy Keyvani; Niklas Schäfer; Asma Milia; Lale Umutlu; Daniela Pierscianek; Martin Stuschke; Michael Forsting; Ulrich Sure; Christoph Kleinschnitz; Gerald Antoch; Patrick M Colletti; Domenico Rubello; Ken Herrmann; Ulrich Herrlinger; Björn Scheffler; Ralph A Bundschuh
Journal:  J Neurooncol       Date:  2021-01-27       Impact factor: 4.130

Review 4.  Amino acid PET and MR perfusion imaging in brain tumours.

Authors:  Christian P Filss; Francesco Cicone; Nadim Jon Shah; Norbert Galldiks; Karl-Josef Langen
Journal:  Clin Transl Imaging       Date:  2017-03-13

Review 5.  How we read: the combined use of MRI and novel PET tracers for the characterisation and treatment planning of masses in neuro-oncology.

Authors:  Arian Lasocki; Rodney J Hicks
Journal:  Cancer Imaging       Date:  2019-08-19       Impact factor: 3.909

6.  Reference values of physiological 18F-FET uptake: Implications for brain tumor discrimination.

Authors:  Brigitte Fuenfgeld; Philipp Mächler; Dorothee R Fischer; Giuseppe Esposito; Elisabeth Jane Rushing; Philipp A Kaufmann; Paul Stolzmann; Martin W Huellner
Journal:  PLoS One       Date:  2020-04-17       Impact factor: 3.240

7.  Tumefactive multiple sclerosis versus high-grade glioma: A diagnostic dilemma.

Authors:  Heath David French
Journal:  Surg Neurol Int       Date:  2021-05-03

8.  Tumefactive multiple sclerosis versus high grade glioma: A diagnostic dilemma.

Authors:  Heath French; Ariadna Fontes-Villalba; Monish Maharaj; Catherine Soo Yee Naidoo; Kartik Bhatia; Amanda Paterson; Raymond Cook; John Parratt
Journal:  Surg Neurol Int       Date:  2022-04-15

Review 9.  Molecular imaging of multiple sclerosis: from the clinical demand to novel radiotracers.

Authors:  Matteo Bauckneht; Selene Capitanio; Stefano Raffa; Luca Roccatagliata; Matteo Pardini; Caterina Lapucci; Cecilia Marini; Gianmario Sambuceti; Matilde Inglese; Paolo Gallo; Diego Cecchin; Flavio Nobili; Silvia Morbelli
Journal:  EJNMMI Radiopharm Chem       Date:  2019-04-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.